Nucleus RadioPharma, a fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the closing of a Series A extension round with new investor AstraZeneca. Concurrent with the financing, Tyrell Rivers, PhD, Executive Director of Corporate Ventures at AstraZeneca, was named to the Board of Directors.